Sir Chanticleer schreef op 29 juni 2018 14:09:
RBC: GLPG removing CF value almost completely from our model (previous POS was 15%). Stock downside could be limited by modest expectations going in and promise of lead asset filgotinib - which has low-risk upcoming catalysts. Lowering tgt to $94.